Formulation and Characterization of Floating Gelucire Matrices of Metoprolol Succinate

Abstract

The aim of the current investigation was to formulate floating sustained-release matrices of metoprolol succinate using Gelucire 43/01 and Gelucire 44/14 by a melt-solidification technique. The in vitro and in vivo characteristics of the prepared matrices were evaluated. The in vitro drug release studies performed in 0.1 N HCl revealed a proportional increase in drug release pattern with increased concentration of Gelucire 44/14.Drug release data were analyzed by various mathematical models, and the mean dissolution time, Dissolution Efficiency, and similarity factor (f 2 ) were determined in optimizing formulations. Differential scanning calorimetry and Fourier transform infrared spectroscopy showed no chemical interaction between drug and carriers studied. The in vitro floating characteristics of Gelucire matrices were greater than 12 h with good in vivo gastric retention. The results indicate that Gelucire 43/01 is an appropriate carrier for the development of sustained-release floating drug delivery systems and Gelucire 44/14, a highly hydrophilic and lipophilic balance (HLB) excipient, acts as release enhancer in the formulations studied.

HPLC method development for determination of metoprolol, telmisartan and cilnidipine simultaneously using response surface design

“…It is used to treat hypertension and various cardiovascular disorders. It is chemically known as (±) 1-(isopropyl amino)-3-[p-(2-methoxyethyl) phenoxy]-2-propanol succinate (2:1) (Gad, 2014;Siripuram et al, 2010). Cilnidipine Figure 1b is chemically 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5pyridine carboxylic acid-2methoxy ethyl-(2E)-3-phenyl-propenylester (Kim et al, 2006).…”

Preparation and evaluation of cefuroxime axetil gastro-retentive floating drug delivery system via hot melt extrusion technology

“…Glycerideconjugated lipids are available with varying degrees of hydrophobicity and melt at low temperatures to aid in thermal processing, making them ideal carriers for controlled drug delivery (Aiṅaoui and Vergnaud, 1998). Siripuram et al demonstrated the sustained release properties of Gelucire® 43/01 (Siripuram et al, 2010).…”